Streetwise Potash Sponsors
Select a name to see a detailed description, expert analysis and contact information.
|"DXD timeline to have a commercial product is much shorter than a traditional biotech company developing a new drug."|
|"BAR has a treasured land package ripe for future discoveries."|
|"We anticipate an NI 43-101 resource on RVG's Beartrack by mid-2018."|
|"KDX increased its revolving credit facility by $10M, to $45M."|
|"IMV could forge licensing deals for DPX-Survivac and DPX-RSV; we are maintaining our Speculative Buy rating."|